Gearing up new partnerships, Boehringer gets an option to buy a new player in oncolytic viruses in $230M deal
Boehringer Ingelheim is actively joining the hunt for the next big oncolytic virus program in the hot and happening cancer field.
After backing a small …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
